宫颈癌维持治疗研究进展

doi:10.3760/cma.j.cn371439-20220602-00082

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (7): 430-435.doi: 10.3760/cma.j.cn371439-20220602-00082

宫颈癌维持治疗研究进展

彭琛^1,², 谢印通³, 张昕⁴, 谢鹏^2,⁵()

1.山东第一医科大学（山东省医学科学院）研究生部,济南 250117
2.山东省肿瘤防治研究院（山东省肿瘤医院）妇瘤科,山东第一医科大学（山东省医学科学院）,济南 250117
3.山东省临沭县中医医院影像科,临沂 276700
4.山东省临沂市中医医院影像科,临沂 276000
5.山东省聊城市人民医院妇科,聊城 252000

收稿日期:2022-06-02 修回日期:2022-06-08 出版日期:2022-07-08 发布日期:2022-09-19
通讯作者: 谢鹏 E-mail:xiepengro@126.com
基金资助:
山东省医药卫生科技发展计划(202009030673);山东省肿瘤医院培育项目(2020-PYB22);白求恩肿瘤放疗转化医学研究基金(flzh202125);山东省医学会临床科研基金(YXH2022ZX02151);山东省重点研发计划(2020RKC03013)

Research progress of maintenance therapy for cervical cancer

Peng Chen^1,², Xie Yintong³, Zhang Xin⁴, Xie Peng^2,⁵()

1. Department of Graduate, Shandong Frist Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
2. Department of Gynecological Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
3. Department of Medical Imaging, Linshu County Traditional Chinese Medicine Hospital of Shandong Province, Linyi 276700, China
4. Department of Medical Imaging, Linyi Traditional Chinese Medicine Hospital, Shandong Province, Linyi 276000, China
5. Department of Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng 252000, China

Received:2022-06-02 Revised:2022-06-08 Online:2022-07-08 Published:2022-09-19
Contact: Xie Peng E-mail:xiepengro@126.com
Supported by:
Healthy Science Development Plan of Shandong Province of China(202009030673);Shandong Cancer Hospital Project(2020-PYB22);Bethune Translational Research Foundation of Radiation Oncology(flzh202125);Shandong Medical Association Clinical Research Foundation(YXH2022ZX02151);Key Research and Development Plan of Shandong Province of China(2020RKC03013)

摘要/Abstract

摘要：

宫颈癌是威胁女性生命健康的常见恶性肿瘤。其中复发或晚期宫颈癌预后较差,且往往接受过手术治疗、放疗、化疗等,在选择治疗方案时更加棘手,即使经过最有效的治疗手段,晚期宫颈癌治疗失败率仍较高。得益于肿瘤细胞信号通路相关靶点及免疫治疗,尤其是免疫检查点抑制剂的研究进展,宫颈癌维持治疗取得了新的突破。靶向维持治疗、免疫维持治疗、多药联合维持治疗是目前宫颈癌维持治疗的热门领域。

关键词: 宫颈肿瘤, 复发, 肿瘤转移, 维持治疗

Abstract:

Cervical cancer is a common malignant tumor that threatens women's life and health. Among them, the prognosis of recurrent or advanced cervical cancer is poor, and such patients often receive surgical treatment, radiotherapy, chemotherapy, etc., which makes it more difficult to choose a treatment plan. Even after the most effective treatment methods, the treatment failure rate of advanced cervical cancer is still high. Thanks to the research progress of tumor cell signaling pathway-related targets and immunotherapy, especially immune checkpoint inhibitors, new breakthroughs have been made in cervical cancer maintenance therapy. Targeted maintenance therapy, immune maintenance therapy, and multi-drug combination maintenance therapy are currently popular areas of cervical cancer maintenance therapy.

Key words: Uterine cervical neoplasms, Recurrence, Neoplasm metastasis, Maintenance treatment

彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.

Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.

参考文献 39

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84. DOI: 10.6004/jnccn.2019.0001. doi: 10.6004/jnccn.2019.0001
[3]	Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer[J]. Radiother Oncol, 2018, 127(3): 404-416. DOI: 10.1016/j.radonc.2018.03.003. doi: S0167-8140(18)30135-X pmid: 29728273
[4]	Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370(8): 734-743. DOI: 10.1056/NEJMoa1309748. doi: 10.1056/NEJMoa1309748
[5]	Leath CA 3rd, Straughn JM Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials[J]. Gynecol Oncol, 2013, 129(1): 251-257. DOI: 10.1016/j.ygyno.2012.12.035. doi: 10.1016/j.ygyno.2012.12.035
[6]	Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390(10103): 1654-1663. DOI: 10.1016/S0140-6736(17)31607-0. doi: 10.1016/S0140-6736(17)31607-0
[7]	Godoy-Ortiz A, Plata Y, Alcaide J, et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients[J]. Clin Transl Oncol, 2018, 20(7): 922-927. DOI: 10.1007/s12094-017-1808-x. doi: 10.1007/s12094-017-1808-x pmid: 29222647
[8]	Suzuki K, Nagao S, Shibutani T, et al. Phase Ⅱ trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer[J]. Gynecol Oncol, 2019, 154(3): 554-557. DOI: 10.1016/j.ygyno.2019.05.018. doi: 10.1016/j.ygyno.2019.05.018
[9]	Zhu J, Song C, Zheng Z, et al. Anlotinib in Chinese patients with recurrent advanced cervical cancer: a prospective single-arm, open-label phase Ⅱ trial[J]. Front Oncol, 2021, 11: 720343. DOI: 10.3389/fonc.2021.720343. doi: 10.3389/fonc.2021.720343
[10]	Xia X, Jiang W, Qi W, et al. Clinical efficacy and safety of apatinib for the treatment of patients with metastatic, recurrent cervical cancer after failure of radiotherapy and first-line chemotherapy: a prospective study[J]. Oncol Res Treat, 2020, 43(12): 649-655. DOI: 10.1159/000510355. doi: 10.1159/000510355
[11]	Li N, Wang Z, Yuan G, et al. An oral small molecule VEGFR2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study[J]. J Oncol, 2020, 2020: 3852373. DOI: 10.1155/2020/3852373. doi: 10.1155/2020/3852373
[12]	Xiao Y, Cheng H, Wang L, et al. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study[J]. J Gynecol Oncol, 2020, 31(1): e2. DOI: 10.3802/jgo.2020.31.e2. doi: 10.3802/jgo.2020.31.e2
[13]	Yang H, Chen M, Mei Z, et al. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: a retrospective study[J]. Cancer Med, 2021, 10(13): 4282-4290. DOI: 10.1002/cam4.3966. doi: 10.1002/cam4.3966
[14]	Zhang L, Chen L, Yu H. Phase Ⅱ study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients[J]. Invest New Drugs, 2020, 38(4): 1186-1191. DOI: 10.1007/s10637-019-00858-5. doi: 10.1007/s10637-019-00858-5
[15]	de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or meta static solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(3): 383-393. DOI: 10.1016/S1470-2045(18)30859-3. doi: 10.1016/S1470-2045(18)30859-3
[16]	Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2021, 22(5): 609-619. DOI: 10.1016/S1470-2045(21)00056-5. doi: 10.1016/S1470-2045(21)00056-5
[17]	A randomized, open-label, phase 3 trial of tisotumab vedotin vs investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer[EB/OL]. [2021-2-22][2022-7-26]. https://clinicaltrials.gov/ct2/show/NCT04697628?term=NCT04697628&draw=2&rank=1.
[18]	Vergote IB, Concin N, Mirza MR, et al. 1064TiP—phase Ⅰ/Ⅱ trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)[J]. Ann Oncol, 2019, 30(Supplement 5): v433-v434. DOI: 10.1093/annonc/mdz250.072. doi: 10.1093/annonc/mdz250.072
[19]	A phase 1b/2 open-label trial of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination with other agents in subjects with recurrent or stage ⅣB cervical cancer[EB/OL]. [2019-2-27] [2022-5-20]. https:/clinicaltrials.gov/ct2/show/NCT03786081?term=NCT03786081&draw=2&rank=1.
[20]	Benson R, Pathy S, Kumar L, et al. Locally advanced cervical cancer—neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: a phase Ⅱ study[J]. J Cancer Res Ther, 2019, 15(6): 1359-1364. DOI: 10.4103/jcrt.JCRT_39_18. doi: 10.4103/jcrt.JCRT_39_18 pmid: 31898673
[21]	Pignata S, Scambia G, Lorusso D, et al. The MITO CERV-2 trial: a randomized phase Ⅱ study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer[J]. Gynecol Oncol, 2019, 153(3): 535-540. DOI: 10.1016/j.ygyno.2019.03.260. doi: S0090-8258(19)30495-0 pmid: 30979589
[22]	Carlson JJ, Italiano A, Brose MS, et al. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer[J]. Am J Manag Care, 2022, 28(2 Suppl): S26-S32. DOI: 10.37765/ajmc.2022.88845. doi: 10.37765/ajmc.2022.88845
[23]	Thaker PH, Salani R, Brady WE, et al. A phase Ⅰ trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)[J]. Ann Oncol, 2017, 28(3): 505-511. DOI: 10.1093/annonc/mdw635. doi: 10.1093/annonc/mdw635 pmid: 27998970
[24]	Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ⅰb KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36): 4035-4041. DOI: 10.1200/JCO.2017.74.5471. doi: 10.1200/JCO.2017.74.5471
[25]	Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265
[26]	Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase Ⅰ/Ⅱ CheckMate 358 trial[J]. J Clin Oncol, 2019, 37(31): 2825-2834. DOI: 10.1200/JCO.19.00739. doi: 10.1200/JCO.19.00739 pmid: 31487218
[27]	Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer[J]. N Engl J Med, 2022, 386(6): 544-555. DOI: 10.1056/NEJMoa2112187. doi: 10.1056/NEJMoa2112187
[28]	Prospective randomized phase Ⅱ trial comparing doxorubicin alone versus atezolizumab alone versus doxorubicin and atezolizumab in recurrent cervical cancer[EB/OL]. [2017-8-30] [2021-1-27]. https://clinicaltrials.gov/ct2/show/NCT03340376?term=NCT03340376&draw=2&rank=1.
[29]	Mayadev J, Nunes AT, Li M, et al. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase Ⅲ, randomized, double-blind, multicenter study[J]. Int J Gynecol Cancer, 2020, 30(7): 1065-1070. DOI: 10.1136/ijgc-2019-001135. doi: 10.1136/ijgc-2019-001135 pmid: 32447296
[30]	Update on CALLA phase Ⅲ trial of concurrent use of imfinzi and chemoradiotherapy in locally advanced cervical cancer[EB/OL]. [2022-3-24] [2022-5-20]. https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-im-finzi.html.
[31]	Lheureux S, Butler MO, Clarke B, et al. Association of ipili-mumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma[J]. JAMA Oncol, 2018, 4(7): e173776. DOI: 10.1001/jamaoncol.2017.3776. doi: 10.1001/jamaoncol.2017.3776
[32]	A phase 2, multicenter, single arm, open label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer[EB/OL]. [2020-7-15] [2022-5-28]. https://clinicaltrials.gov/ct2/show/NCT04380805?term=NCT04380805&draw=2&rank=1.
[33]	A multicenter, open-label, phase Ⅱ study of AK104(an anti-PD-1 and anti-CTLA-4 bispecific antibody) in the treatment of recurrent or metastatic cervical cancer[EB/OL]. [2021-4-01] [2022-5-29]. https://clinicaltrials.gov/ct2/show/NCT04868708?term=NCT04868708&draw=2&rank=1.
[34]	double-blind, placebo-controlled phase Ⅲ study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer[EB/OL]. [2021-8-27] [2022-4-27]. https://clinicaltrials.gov/ct2/show/NCT04982237?term=NCT04982237&draw=2&rank=1.
[35]	O'Malley DM, Oaknin A, Monk BJ, et al. LBA34 single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): preliminary results of two independent phase Ⅱ trials[J]. Ann Oncol, 31(Supplement 4):S1164-S1165. DOI: 10.1016/j.annonc.2020.08.2264. doi: 10.1016/j.annonc.2020.08.2264
[36]	Monk BJ, Tewari KS, Hasegawa CK, et al. Patient-reported outcomes from the phase 3 randomized, double-blind, KEYNOTE-826 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer[R]. Phoenix: The Society of Gynecologic Oncology (SGO)2022 Annual Meeting on Women’s Cancer, 2022.
[37]	Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial[J]. J Clin Oncol, 2022, 40(16): 1795-1805. DOI: 10.1200/JCO.21.02091. doi: 10.1200/JCO.21.02091
[38]	Lan C, Shen J, Wang Y, et al. Camrelizumab Plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106. DOI: 10.1200/JCO.20.01920. doi: 10.1200/JCO.20.01920
[39]	Friedman CF, Snyder Charen A, Zhou Q, et al. Phase Ⅱ study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer[J]. J Immunother Cancer, 2020, 8(2): e001126. DOI: 10.1136/jitc-2020-001126. doi: 10.1136/jitc-2020-001126

宫颈癌维持治疗研究进展

Research progress of maintenance therapy for cervical cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[4]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[7]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[8]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[9]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[10]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[11]	马培晗, 张灵敏, 路宁, 张明鑫. 麻醉对肝细胞癌复发转移的影响[J]. 国际肿瘤学杂志, 2023, 50(2): 117-121.
[12]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[13]	吕璐, 孙鹏飞, 崔腾璐. 子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[14]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[15]	赵建昊, 段衍超. 多发性骨髓瘤髓外病变发病机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 55-59.